Engene Holdings WT (ENGNW)

$1.97 -0.13 (-6.19%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -99.92M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 815
Avg Vol 5,100
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 57%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.

Phone: 514 332 4888
Address:
4868 Rue Levy, Suite 220, Montreal, Canada
Latest News on ENGNW
No data available.